<?xml version='1.0' encoding='utf-8'?>
<document id="25417855"><sentence text="Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient."><entity charOffset="77-87" id="DDI-PubMed.25417855.s1.e0" text="everolimus" /><entity charOffset="92-104" id="DDI-PubMed.25417855.s1.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.25417855.s1.e0" e2="DDI-PubMed.25417855.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25417855.s1.e0" e2="DDI-PubMed.25417855.s1.e1" /></sentence><sentence text="Azole antifungals, prescribed prophylactically to avoid severe infections in immunosuppressed organ transplant recipients, can interact with drug substrates of CYP3A4"><entity charOffset="0-5" id="DDI-PubMed.25417855.s2.e0" text="Azole" /></sentence><sentence text=" We report serious adverse effects due to interaction between orally administered voriconazole and everolimus in a renal transplant recipient"><entity charOffset="82-94" id="DDI-PubMed.25417855.s3.e0" text="voriconazole" /><entity charOffset="99-109" id="DDI-PubMed.25417855.s3.e1" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.25417855.s3.e0" e2="DDI-PubMed.25417855.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25417855.s3.e0" e2="DDI-PubMed.25417855.s3.e1" /></sentence><sentence text="" /><sentence text="Despite reduction of the dose of everolimus by a third, the blood trough concentration of everolimus increased considerably in a kidney transplant recipient upon oral administration of voriconazole"><entity charOffset="33-43" id="DDI-PubMed.25417855.s5.e0" text="everolimus" /><entity charOffset="90-100" id="DDI-PubMed.25417855.s5.e1" text="everolimus" /><entity charOffset="185-197" id="DDI-PubMed.25417855.s5.e2" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.25417855.s5.e0" e2="DDI-PubMed.25417855.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25417855.s5.e0" e2="DDI-PubMed.25417855.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25417855.s5.e0" e2="DDI-PubMed.25417855.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25417855.s5.e1" e2="DDI-PubMed.25417855.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25417855.s5.e1" e2="DDI-PubMed.25417855.s5.e2" /></sentence><sentence text=" Everolimus was then discontinued"><entity charOffset="1-11" id="DDI-PubMed.25417855.s6.e0" text="Everolimus" /></sentence><sentence text=" Pneumonia secondary to pulmonary aspergillosis worsened, possibly due to the excessive immunosuppression" /><sentence text="" /><sentence text="Orally administered voriconazole inhibits intestinal and hepatic cytochrome P450-3A4 activity and thereby reduces everolimus metabolism"><entity charOffset="20-32" id="DDI-PubMed.25417855.s9.e0" text="voriconazole" /></sentence><sentence text=" An 80% decrease in dose or discontinuation of everolimus is required when concomitant voriconazole is introduced"><entity charOffset="47-57" id="DDI-PubMed.25417855.s10.e0" text="everolimus" /><entity charOffset="87-99" id="DDI-PubMed.25417855.s10.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.25417855.s10.e0" e2="DDI-PubMed.25417855.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25417855.s10.e0" e2="DDI-PubMed.25417855.s10.e1" /></sentence><sentence text=" Daily blood monitoring of everolimus is warranted until a steady state of concentrations is reached"><entity charOffset="27-37" id="DDI-PubMed.25417855.s11.e0" text="everolimus" /></sentence><sentence text="" /></document>